| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 07/04/2001 | CN1302296A Novel 2-alkyl substituted imidazole compounds |
| 07/04/2001 | CN1302202A Opthalmic solution comprising glycogen |
| 07/04/2001 | CN1302201A Ophthalmic compositions containing galactomannan polymers and borate |
| 07/04/2001 | CN1302183A Xylitol compositions for treating upper respiratory conditions |
| 07/04/2001 | CN1067986C 1H-indole-3-acetic acid hydrazide phospholipid enzyme A2 inhibitors |
| 07/03/2001 | US6255453 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 07/03/2001 | US6255343 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use |
| 07/03/2001 | US6255338 Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors |
| 07/03/2001 | US6255281 Complexing uteroglobin to fibronectin |
| 07/03/2001 | US6254875 Methods for use of OMP26 from Haemophilus influenzae |
| 07/03/2001 | US6254860 Ocular treatment using cyclosporin-A derivatives |
| 07/03/2001 | CA2012115C Iodinated somatostatins |
| 06/30/2001 | CA2293852A1 Procedure for preparing active plant extracts used to trap free radicals; the extracts and compounds and devices containing them |
| 06/28/2001 | WO2001046394A2 Mammalian protein phosphatases |
| 06/28/2001 | WO2001046392A2 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | WO2001046258A2 Transporters and ion channels |
| 06/28/2001 | WO2001046255A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046195A1 Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same |
| 06/28/2001 | WO2001046185A1 Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| 06/28/2001 | WO2001046184A1 3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046168A1 Tryptase inhibitors |
| 06/28/2001 | WO2001046136A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046128A2 Tryptase inhibitors |
| 06/28/2001 | WO2001045751A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | WO2001045713A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method |
| 06/28/2001 | WO2001045703A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | WO2001045689A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 06/28/2001 | WO2001014402A8 Antisense modulation of focal adhesion kinase expression |
| 06/28/2001 | WO2000078322A3 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 06/28/2001 | WO2000071149A3 Therapeutic uses of bpi protein products in humans with otitis media with effusion |
| 06/28/2001 | WO2000070047A3 Full-length molecules expressed in human tissues |
| 06/28/2001 | WO2000066731A3 Recombinant laminin 5 |
| 06/28/2001 | US20010005720 Method of treating chronic progressive vascular scarring diseases |
| 06/28/2001 | DE19957065A1 Screening-Verfahren für Arzneistoffe A screening method for drugs |
| 06/28/2001 | CA2395202A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | CA2395136A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | CA2395007A1 Transporters and ion channels |
| 06/28/2001 | CA2393855A1 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | CA2393724A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | CA2392787A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2392127A1 Tryptase inhibitors |
| 06/28/2001 | CA2392121A1 Tryptase inhibitors |
| 06/28/2001 | CA2389482A1 Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| 06/27/2001 | EP1110554A1 Medicinal compositions for treating eye diseases |
| 06/27/2001 | EP1110551A2 Ocular tension lowering agent |
| 06/27/2001 | EP1109919A2 Rationally designed heparinases derived from heparinase i and ii |
| 06/27/2001 | EP1109907A1 Human cell junction pdz protein |
| 06/27/2001 | EP1109799A1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors |
| 06/27/2001 | EP1109570A2 Method of modulating memory effector t-cells and compositions |
| 06/27/2001 | EP1109555A1 Novel angiogenesis inhibitors |
| 06/27/2001 | EP1109554A2 Pipecolic acid derivatives for vision and memory disorders |
| 06/27/2001 | EP1109546A1 Ophthalmic compositions for treating ocular hypertension |
| 06/27/2001 | EP1109543A1 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| 06/27/2001 | EP1109542A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
| 06/27/2001 | EP1109533A1 Pulmonary delivery of liposome-encapsulated cannabinoids |
| 06/27/2001 | EP0938472B1 15-fluoro prostaglandins as ocular hypotensives |
| 06/27/2001 | EP0862564A4 Photoactivatable compounds for the prevention of intimal hyperplasia and other diseases |
| 06/27/2001 | EP0734261B1 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| 06/27/2001 | EP0701554B1 Novel compounds having a benzisoselen-azoline and -azine structure, method for preparing same and therapeutic uses thereof |
| 06/27/2001 | EP0690720B1 Therapeutic uses of bactericidal/permeability increasing protein products |
| 06/27/2001 | CN1301265A Novel substituted arylhydroxamic acids as metalloproteinase inhibitors |
| 06/27/2001 | CN1301255A Heterocyclically substituted amides, their production and their use |
| 06/27/2001 | CN1301168A Therapeutic dinucleotide and derivatives |
| 06/27/2001 | CN1301161A Serotonergic 5HT receptor compounds for treating ocular and CNS disorders |
| 06/27/2001 | CN1301156A Treatment of T-Helper cell tyre 2 mediated immune diseases with retinoid antagonists |
| 06/26/2001 | US6251950 Administering to the patient an aliphatic-propargylamine or salt for the treatment of acute and chronic diseases in which cell death occurs by apoptosis or for the treatment of premature degeneration of cells in mammals |
| 06/26/2001 | US6251945 Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 06/26/2001 | US6251944 (vitronectin receptor) integrin antagonist, useful for treating angiogenesis, tumor growth, tumor metastasis, osteoporosis and humoral hypercalcemia of malignancy |
| 06/26/2001 | US6251925 An agonists for human beta-3 adrenoceptor |
| 06/26/2001 | US6251917 Benzamidoaldehydes and their use as cysteine protease inhibitors |
| 06/26/2001 | US6251914 Treating cytokine mediated diseases |
| 06/26/2001 | US6251909 Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 06/26/2001 | US6251904 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
| 06/26/2001 | US6251867 Antiangiogenic peptides and methods for inhibiting angiogenesis |
| 06/26/2001 | US6251853 Pertussis toxin (ptx); beta-3 subunit of human g protein with not more than six wd repeat motifs; for the diagnosis of disorders, such as a disease associated with g protein dysregulation (i.e. hypertension) |
| 06/26/2001 | US6251663 Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases |
| 06/21/2001 | WO2001044473A2 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | WO2001044472A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | WO2001044294A2 Compositions and methods for inhibiting endothelial cell proliferation |
| 06/21/2001 | WO2001044268A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 06/21/2001 | WO2001044245A1 Saccharin derivatives as orally active elastase inhibitors |
| 06/21/2001 | WO2001044227A1 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 06/21/2001 | WO2001044212A1 Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
| 06/21/2001 | WO2001043775A2 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | WO2001043773A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 06/21/2001 | WO2001043744A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
| 06/21/2001 | WO2001043737A1 Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina |
| 06/21/2001 | WO2001043731A2 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage |
| 06/21/2001 | WO2001043540A2 Methods for producing transgenic animals |
| 06/21/2001 | WO2001017527A9 Preventive and therapeutic agents for eye diseases |
| 06/21/2001 | CA2395486A1 Saccharin derivatives as orally active elastase inhibitors |
| 06/21/2001 | CA2394600A1 Methods for producing transgenic animals |
| 06/21/2001 | CA2394536A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | CA2394466A1 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | CA2394167A1 Compositions and methods for inhibiting endothelial cell proliferation |
| 06/21/2001 | CA2393762A1 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | CA2390821A1 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage |
| 06/21/2001 | CA2387047A1 Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
| 06/20/2001 | EP1108033A2 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF |
| 06/20/2001 | EP1107973A1 Novel compounds |